Breaking the Trade-off in MPI-Guided Magnetic Hyperthermia by Tailoring the Dynamic Magnetization of Magnetic Nanoparticles via Site-Selective Trace Doping.
OpenAlex 토픽 ·
Nanoparticle-Based Drug Delivery
Characterization and Applications of Magnetic Nanoparticles
Magnetic properties of thin films
Among various theranostic strategies, magnetic particle imaging-guided magnetic hyperthermia therapy (MPI-MHT) stands out for its ability to provide real-time, quantitative imaging alongside controlle
APA
Ruili Zhang, Y Li, et al. (2026). Breaking the Trade-off in MPI-Guided Magnetic Hyperthermia by Tailoring the Dynamic Magnetization of Magnetic Nanoparticles via Site-Selective Trace Doping.. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c05415
MLA
Ruili Zhang, et al.. "Breaking the Trade-off in MPI-Guided Magnetic Hyperthermia by Tailoring the Dynamic Magnetization of Magnetic Nanoparticles via Site-Selective Trace Doping.." Journal of the American Chemical Society, 2026.
PMID
42025591
Abstract
Among various theranostic strategies, magnetic particle imaging-guided magnetic hyperthermia therapy (MPI-MHT) stands out for its ability to provide real-time, quantitative imaging alongside controlled tumor ablation. Nevertheless, its advancement is hindered by the conflicting requirements for dynamic magnetization of magnetic nanoparticles (MNPs), which are crucial for optimizing both the MPI signal and the efficacy of MHT. This complexity makes it challenging to enhance performance synergistically within a single agent. Herein, we present an innovative site-selective doping strategy using trace amounts of cobalt to tailor the dynamic magnetization of MNPs, specifically optimizing key parameters including dynamic susceptibility and relaxation time. The resulting trace cobalt-doped nanoparticles (TCMPs) achieve a 7.4-fold enhancement in the MPI signal and a 12-fold increase in the specific absorption rate for heating compared to the commercial tracer VivoTrax. Furthermore, by engineering TCMPs with genetically modified cell membranes, we fabricate a prostate cancer-targeted MPI-MHT agent, TCMPs@CM, which enables effective visualization and ablation of both subcutaneous and postsurgical residual tumors in mouse models. This study introduces a novel paradigm for the development of high-performance MPI-MHT platforms, demonstrating significant potential for advancing precision cancer theranostics.
같은 제1저자의 인용 많은 논문 (5)
- Recent developments in delirium after oral and maxillofacial free-flap reconstruction.
- Safety and efficacy of traction robot-assisted endoscopic submucosal dissection for early gastric cancer: a randomized pilot trial.
- Split CAR-T cells targeting CD312 and TIM-3 for acute myeloid leukemia to reduce the risk of antigen escape.
- Fully human anti-B7-H4 antibody induces lysosome-dependent ferroptosis to reverse primary resistance to PD-1 blockade.
- A rare false-positive uptake: orbital conjunctival cyst mimicking metastasis on post-therapeutic radioiodine scan in thyroid cancer.